27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
- The FDA has approved Scynexis Inc's (NASDAQ:SCYX) Brexafemme (ibrexafungerp tablets) for oral use in patients with vulvovaginal candidiasis (VVC), also known as a vaginal yeast infection.
- Brexafemme represents the first approved drug in a novel antifungal class in more than 20 years and is the first and only treatment for vaginal yeast infections, both oral and non-azole.
- The approval is based on positive results from two Phase 3 studies in which oral ibrexafungerp demonstrated efficacy and a favorable tolerability profile in women with VVC.
- Scynexis has partnered with Amplity Health to support the U.S. commercialization of Brexafemme, with a commercial launch scheduled in the second half of 2021.
- The company will host a conference call today at 8:30 a.m. ET.
- Price Action: SCYX shares were up 0.80% at $10.05 in the premarket session on the last check Wednesday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!